Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2020 Earnings Conference Call - Final Transcript
Oct 27, 2020 • 05:00 pm ET
Emil D. Kakkis
scalability of our HeLa manufacturing platform that is vital for larger patient populations. And behind that, we have other large indications moving ahead. This includes the newly announced Duchenne program, which is a competitive space, one that we believe we are uniquely able to bring forward.
And beyond the gene therapy space, we have the exciting Angelman data from yesterday that supports that we have a potent molecule in that disease and we have a plan in place to work through the safety issue to advance this product forward for this large and severe disease. Over the last couple of years, we've gone from a clinical stage biotech to a diversified commercial rare disease leader with a number of large opportunities ahead of us.
We will continue executing across all facets of our business with our dedicated employees across the globe and a strong balance sheet and growing revenue.
Let's move on to your questions. Operator, please provide the instructions for the Q&A portion of the call.